Search Results
Your search for ,WHo matches 20390 pages
Showing 13401 - 13450Dave, Dave, Dave
It was 1983, and I was in my third year as an attending physician at a major East Coast university medical center and just 5 years out of fellowship. As was common at the time, I saw and treated all malignancies except leukemia and gynecologic cancers. In the middle of a typically busy day at the ...
FDA Approves Daratumumab in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Multiple Myeloma
On November 21, 2016, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone, or bortezomib (Velcade) and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior...
Center for Leukemia and Lymphoma Research at UNMC Renamed Dr. James O. Armitage Center for Leukemia and Lymphoma Research
The University of Nebraska Board of Regents voted to rename an area of the University of Nebraska Medical Center (UNMC) in honor of a longtime professor who has made extraordinary contributions to the institution. The Center for Leukemia and Lymphoma Research, established in 2003, was renamed by...
Pooled Analysis of Outcome With Nivolumab Alone or With Ipilimumab in Advanced Mucosal or Cutaneous Melanoma
A pooled analysis of outcomes in patients receiving nivolumab (Opdivo) or nivolumab plus ipilimumab (Yervoy) for advanced mucosal or cutaneous melanoma in clinical trials was reported by D’Angelo et al in the Journal of Clinical Oncology. The pooled analysis involved 889 patients who...
CAP/ASCP/ASCO Guideline on HER2 Testing and Clinical Decision-Making in Gastroesophageal Adenocarcinoma
As reported by Angela N. Bartley, MD, of St Joseph Mercy Hospital, Ann Arbor, and colleagues in the Journal of Clinical Oncology, the College of American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), and ASCO have released a guideline on HER2 testing and clinical...
Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions
Memorial Sloan Kettering Cancer Center, Rockefeller University, and Weill Cornell Medicine have announced that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd and health-care investment firms Bay City Capital ...
Michael O’Connell, MD, Receives the 2016 ACCC Clinical Research Award
Michael O’Connell, MD, received the Association of Community Cancer Centers (ACCC) 2016 Clinical Research Award in recognition of the significant and positive impact of his research on the oncology patient, family, and the community. ACCC President Jennie R. Crews, MD, MMM, FACP, accepted the...
Carrie Lee, MD, MPH, Named Chair-Elect of AACI’s Clinical Research Initiative Steering Committee
Carrie Lee, MD, MPH, Medical Director of the University of North Carolina (UNC) Lineberger’s Clinical Protocol Office, has been appointed the Chair-Elect of the Association of American Cancer Institute’s (AACI) Clinical Research Initiative Steering Committee. Her Chair term will start in 2017. Dr. ...
Zhu Chen, MD, PhD, and Hugues de Thé, MD, PhD, to Present 2016 ASH Ernest Beutler Lecture
The American Society of Hematology (ASH) will honor Zhu Chen, MD, PhD, of Shanghai Institute of Hematology, and Hugues de Thé, MD, PhD, of Collège de France, with the 2016 Ernest Beutler Lecture and Prize for their significant research advances in the area of acute promyelocytic leukemia (APL)....
The Future of Health Care in America: Which Corridor?
It was mid-morning, and I was walking along one of the long corridors in our hospital, attending to clinical duties. From a distance, I noticed this elderly couple walking in the opposite direction. As we got closer, it became obvious that the elderly gentleman appeared winded and was looking...
Sleep Disruption in Cancer Survivors: Yoga Offers a Low-Risk Intervention With High Potential for Benefit
Impaired sleep quality is a concerning problem for many patients with cancer, and pharmacologic treatments come with many negative effects. Several small studies indicate that yoga improves persistent fatigue, sleep disturbance, anxiety, and quality of life, in addition to reducing the need for ...
How When Breath Becomes Air Is Helping the Public—and Physicians—Confront Their Mortality
It should not come as a surprise to anyone who has read Dr. Paul Kalanithi’s brilliant—and unforgettable—memoir, When Breath Becomes Air (Random House, 2016), that nearly a year after publication, it remains on The New York Times best-seller list, its popularity only increasing with time. Written...
Making Peace With Cancer
Next to me sounds the buzzing of my Lympha Press machine, which substitutes for the constant visits of the physiotherapist who performs the lymph drainage. This gives me more freedom, and we have more privacy at home. I can use the machine whenever I need it, and my 5-year-old daughter, Christina, ...
Anne Gross, PhD, RN, NEA-BC, FAAN, Named Senior Vice President of Patient Care Services and Chief Nursing Officer at Dana-Farber
Anne Gross, PhD, RN, NEA-BC, FAAN, has been named Senior Vice President for Patient Care Services and Chief Nursing Officer at Dana-Farber Cancer Institute, effective December 1, 2016. Dr. Gross joined Dana-Farber in 2002 after 12 years at Cambridge Health Alliance as the nursing leader in...
A Lung Cancer Specialist Talks About Value in Cancer Care
Over the past few years, the term value-based cancer care has become integrated into the vernacular of the oncology community. Value is a subjective term, which is defined largely by its clinical setting. However, value in cancer care is evaluated by the multiple stakeholders involved in the...
Cary A. Presant, MD, FACP, FASCO, Receives ACCC David King Community Clinical Scientist Award
The Association of Community Cancer Centers (ACCC) honored Cary A. Presant, MD, FACP, FASCO, with the prestigious David King Community Clinical Scientist Award, for his demonstrated leadership in the development, participation, and evaluation of clinical studies for cancer patients. Throughout his ...
AMA Adopts Ethical Guidance on Team-Based Health Care
Team-based health-care models are emerging as preferred methods for providing coordinated, cost-effective and high-quality health care for patients. Earlier this month, the American Medical Association (AMA) announced its adoption of ethical guidance for physicians as leader-members of care ...
Pembrolizumab in First-Line Treatment of Metastatic Non–Small Cell Lung Cancer
On October 24, 2016, pembrolizumab (Keytruda) was approved for use in patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have high programmed cell death ligand 1 (PD-L1) expression (tumor proportion score ≥ 50%) as determined by a U.S. Food and Drug Administration...
At ESMO 2016, Many Phase III Trials Fail to Meet Primary Endpoints
The 2016 European Society for Medical Oncology (ESMO) Congress revealed many important positive findings from key trials in a number of tumor types, but many highly anticipated phase III trials in advanced disease failed to meet their primary endpoints. The ASCO Post has summarized several of these ...
Anti–PD-1 Contenders in Advanced Urothelial Cancer
Immunotherapy with anti–PD-1 (programmed cell death protein 1) and anti–PD-L1 (programmed cell death ligand 1) agents continues to advance in metastatic urothelial cancer, with positive showings in two clinical trials presented at the 2016 European Society for Medical Oncology (ESMO) Congress. The...
Locally Advanced Esophageal Cancer Outcomes Improved With Neoadjuvant Therapy
In studies presented at the 2016 European Society for Surgical Oncology (ESMO) Congress, two different neoadjuvant treatment approaches improved the outcomes of patients with esophageal cancer. Investigators from the Australasian Gastro-Intestinal Trials Group (AGITG) reported that the addition of...
Numerous ESMO Presentations Focused on Anti–PD-1 Therapy in Lung Cancer and Melanoma
The 2016 European Society for Medical Oncology (ESMO) Congress was jam-packed with studies of the anti–programmed cell death protein 1 (PD-1) antibodies in non–small cell lung cancer and melanoma, where they have clearly changed the treatment paradigm. Here is a roundup of some of those trials,...
Clinical Strategies for Improving Endocrine Therapy in Metastatic Breast Cancer
Most women with hormone receptor–positive breast cancer receive endocrine therapy as part of their treatment, but “the reality is that patients who receive antihormone therapy in the metastatic disease setting ultimately develop disease progression, ” William J. Gradishar, MD, stated at the 18th...
Androgen Receptor Antagonists May Meet ‘Unmet Need’ in Triple-Negative Breast Cancer
Although there are no androgen receptor antagonists currently approved for the treatment of breast cancer, clinical trials indicate that these agents benefit some patients with triple-negative breast cancer, Tiffany A. Traina, MD, told participants at the 18th Annual Lynn Sage Breast Cancer...
Lack of Standardized Definitions of Cutaneous T-Cell Lymphomas Hampers the Collection of Reliable Data
Cutaneous T-cell lymphomas are a heterogeneous group of cancers. Some subtypes of cutaneous T-cell lymphomas are often misdiagnosed as benign skin diseases, making it challenging to gather reliable epidemiologic data. At the 3rd World Congress of Cutaneous Lymphomas (sponsored by the International...
Phase III Trial Shows Ado-Trastuzumab Emtansine Noninferior to Trastuzumab/Taxane in HER2-Positive Breast Cancer
In the phase III MARIANNE trial reported in the Journal of Clinical Oncology, Perez et al found that ado-trastuzumab emtansine (formerly known as T-DM1; Kadcyla) was associated with noninferior progression-free survival compared with trastuzumab (Herceptin) plus taxane in patients with...
ASCO Quality Improvement Grant Spotlight: The Ralph Lauren Center for Cancer Care
In 2016 and 2017, a team from The Ralph Lauren Center for Cancer Care (RLCCC) is participating in an ASCO Quality Improvement Grant program, which is supported by the Stavros Niarchos Foundation. The grant program aims to improve the delivery of cancer care in medically underserved communities by...
Apply for ASCO Health Policy Fellowship to Improve Skills Needed to Shape Cancer Policy
ASCO is now accepting applications for its prestigious Health Policy Fellowship, a 1-year fellowship opportunity designed to give early-career oncologists the unique skills necessary to monitor and shape the regulatory and legislative policies that directly affect the practice environment and...
Research Highlights From the 2016 Palliative Care in Oncology Symposium
More than 650 attendees gathered in San Francisco on September 9 and 10 for the 2016 Palliative Care in Oncology Symposium, focusing on the theme of “Patient-Centered Care Across the Cancer Continuum.” Research presented during the Symposium demonstrated how integrating palliative care into cancer...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Albania
The ASCO Post is pleased to present this special focus on the worldwide cancer burden. The aim of this special feature is to highlight the global cancer burden for various countries of the world. For the convenience of the reader, each issue will focus on one country from one of the six regions of ...
Adult Survivors of Childhood Cancers Report Long-Term Health Issues
Although progress in treatment and supportive care for children with cancer has resulted in improved survival of these patients, some survivors experience ongoing medical conditions from their cancer or its treatment, including poor general health, poor mental health, functional impairment,...
Updated ASTRO Guideline Expands Pool of Suitable Candidates for Accelerated Partial-Breast Irradiation
On November 17, the American Society for Radiation Oncology (ASTRO) issued an updated clinical practice statement for accelerated partial-breast irradiation for early-stage breast cancer. The updated guideline reflects recent evidence that greater numbers of patients can benefit from accelerated...
High-Throughput Sequencing of T-Cell Receptors May Transform Diagnosis and Treatment of Cutaneous T-Cell Lymphomas
High-throughput sequencing of T-cell receptors may be a solution to some of the challenges confronting oncologists who treat cutaneous T-cell lymphomas. According to experts who presented talks on high-throughput sequencing of T-cell receptors at the 3rd World Congress of Cutaneous Lymphoma...
Novel Urine Test May Predict High-Risk Cervical Cancer
Johns Hopkins Medicine specialists reported they have developed a urine test for the likely emergence of cervical cancer that is highly accurate compared to other tests based on genetic markers derived directly from cervical tissue. The new urine test, they said, is different because it analyzes...
Cautious Optimism About Olaratumab in Soft-Tissue Sarcoma
The current plethora of drugs in development for oncology is leading to the testing of novel agents in common as well as rare diseases. Targeted therapies have been a focus of great interest in soft-tissue sarcomas, with testing of a variety of oral tyrosine kinase inhibitors leading to the...
Fulminant, Fatal Myocarditis Reported in Two Patients After Starting Combined Immune Checkpoint Blockade Treatment
In an article in The New England Journal of Medicine, Johnson et al reported the occurrence of fulminant, fatal immune-related myocarditis in two patients who received combined ipilimumab (Yervoy) and nivolumab (Opdivo) for metastatic melanoma. Patient Courses One patient was a 65-year-old woman...
Cabozantinib Shows Activity in Advanced RET-Rearranged NSCLC
In a phase II trial reported in The Lancet Oncology, Drilon et al found that cabozantinib (Cabometyx) produced responses in some patients with advanced RET-rearranged non–small cell lung cancer (NSCLC). RET rearrangements are found in 1% to 2% of NSCLCs. In the single-arm study, 25 evaluable ...
Studies Confirm Ceritinib’s Benefit in ALK-Positive Patients
For patients with advanced non–small cell lung cancer (NSCLC) harboring the ALK gene rearrangement, ceritinib (Zykadia) provided longer progression-free survival than chemotherapy in patients previously treated with chemotherapy and crizotinib (Xalkori), but gastrointestinal toxicity was...
Supriya Saha, MD, PhD, Opens Laboratory to Study Liver Cancer at Fred Hutch Cancer Research Center
The Cholangiocarcinoma Foundation recently announced the opening of the Saha Laboratory for Liver Cancer Translational Research at the Fred Hutchinson Cancer Research Center in Seattle. Supriya Saha, MD, PhD, has joined scientists there to study the prevention, detection, and treatment of...
Neoadjuvant Nivolumab Appears Safe and Feasible in Lung Cancer
Neoadjuvant immunotherapy with the programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo) is safe and feasible in early-stage non–small cell lung cancer (NSCLC). The results come from the first report of PD-1 blockade prior to surgery in this tumor, according to Patrick Forde, MD, of...
Immunotherapy Clinical Trials Actively Recruiting Patients With Non–Small Cell Lung Cancer
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on immunotherapy as treatment for non–small cell lung cancer (NSCLC). These studies are researching programmed cell death ligand 1 (PD-L1) antibody therapy; hypofractionated...
The Emergence of Philanthropy to Fund High-Risk, High-Reward Cancer Research
Earlier this year, Sean Parker, the cofounder of the music streaming service Napster and an early president of Facebook, joined a growing list of entrepreneurs who are committing large portions of their wealth to funding cancer research. In April, Mr. Parker announced he was donating $250 million...
Memorial Sloan Kettering Long Island Branch Expands Site, Services
The Commack, Long Island–based hospital of Memorial Sloan Kettering (MSK) Cancer Center was opened in 2002, providing personalized cancer care closer to home for individuals living on eastern Long Island. Now, more than 14 years later, MSK is reinforcing its commitment to the local community in...
Expert Point of View: Axel Le Cesne, MD
“The debate about perioperative chemotherapy in localized high-grade soft-tissue sarcoma is never-ending. Can this study resolve the debate?” asked formal discussant Axel Le Cesne, MD, of the Institute de Cancerologie Gustave-Roussy, Villejuif, France. “Surgery remains the standard of care for all ...
Vaccine Therapy in Metastatic Renal Cell Carcinoma: Past, Present, and Future
As reviewed in this issue of The ASCO Post, Brian Rini, MD, and colleagues recently reported results from the phase III IMPRINT trial,1 which randomized HLA-A*02–positive patients with treatment-naive metastatic clear cell variant renal cell carcinoma, in favorable- and intermediate- risk...
Neoadjuvant Chemotherapy in High-Risk Soft-Tissue Sarcoma: A New Standard?
For the first time, a randomized trial has provided good evidence to support the use of neoadjuvant chemotherapy for treatment of high-risk soft-tissue sarcoma of the extremities or trunk wall.1 But the findings of the study were surprising, because neoadjuvant chemotherapy with one-size-fits-all...
Expert Point of View: Sandro Pignata, MD
“This study represents a significant step forward in the treatment of recurrent ovarian cancer,” stated formal discussant Sandro Pignata, MD, of the IRCCS National Cancer Institute “Fondazione G. Pascale,” Naples, Italy. He highlighted some key factors: Patients selected for the study were those...
‘Breakthrough’ in Recurrent Ovarian Cancer: Niraparib Extends Progression-Free Survival in Platinum-Sensitive Disease
A landmark study showed that the investigational PARP (poly ADP-ribose polymerase) 1/2 inhibitor niraparib, when used as maintenance therapy, significantly improves the outcome of platinum-sensitive recurrent ovarian cancer. Specifically, niraparib significantly prolonged progression-free survival ...
Optimizing Allogeneic Stem Cell Transplantation in Myelofibrosis
Allogeneic hematopoietic stem cell transplantation is the only potentially curative treatment for myelofibrosis. The ASCO Post asked an expert in this field, Ayalew Tefferi, MD, how and when he uses stem cell transplant in myelofibrosis, which is a topic he outlined in greater detail in the...
Recent Progress and Concepts in Pancreatic Cancer
November is National Pancreatic Cancer Awareness Month, the impetus for this article. Pancreatic cancer is a huge health challenge. It's the eighth most common cancer in the United States and the fourth most common cause of cancer deaths but is expected to become the second most common cause of...
